Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis

15 September 2026 · By · Wire by Fusion42

Published

15 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

The FDA has accepted the new drug application (NDA) for bezuclastinib to treat advanced systemic mastocytosis, setting a target decision date of June 29, 2027, based on positive data from the phase 2 APEX trial showing strong overall response rates.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your drug in development for rare blood cancers faces a clearer US market entry with this FDA NDA acceptance. Prepare for accelerated commercial and medical planning to capitalise on this approval timeline.

◆ Coverage

1 source · 15 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbezuclastinibsystemic-mastocytosisfda-ndaclinical-trialapex-trial